drugset
drugset / Trial / NCT05610657

A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

NCT05610657 ↗

Phase 1 Completed 20 enrolled Agios Pharmaceuticals, Inc.
NaSingle-groupOpen-labelBasic science

Summary

The primary purpose of this study is to compare the pharmacokinetics (PK) of a single oral dose of mitapivat in participants with moderate hepatic impairment to that in matched healthy control participants with normal hepatic function.

Timeline

Start
2023-01-10
Primary completion
2023-07-21
Completion
2023-07-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitapivat Small molecule — Oral

Indications

No indication recorded.